Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Novartis
Federal Trade Commission
US Department of Justice
Chinese Patent Office
Colorcon
Mallinckrodt
UBS
AstraZeneca
Fish and Richardson

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,284,767

« Back to Dashboard

Which drugs does patent 6,284,767 protect, and when does it expire?


Patent 6,284,767 protects KALETRA and is included in three NDAs. There have been two Paragraph IV challenges on Kaletra.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty patent family members in twenty-three countries.

Summary for Patent: 6,284,767

Title: Retroviral protease inhibiting compounds
Abstract:A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Inventor(s): Sham; Hing Leung (Vernon Hills, IL), Norbeck; Daniel W. (Grayslake, IL), Kempf; Dale J. (Libertyville, IL), Chen; Xiaoqi (San Mateo, CA), Betebenner; David A. (Lawrenceville, NJ), Herrin; Thomas R. (Waukegan, IL), Kumar; Gondi N. (Newbury Park, CA), Lipari; John M. (Racine, WI), Alani; Laman (Morris Plains, NJ), Ghosh; Soumojeet (Lindenhurst, IL), Gao; Rong R. (Edison, NJ), Kaul; Dilip (Edison, NJ)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/207,873
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226-001Sep 15, 2000DISCNNoNo► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000AARXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,284,767

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,968,707Retroviral protease inhibiting compounds► Subscribe
5,914,332 Retroviral protease inhibiting compounds► Subscribe
6,472,529 Retroviral protease inhibiting compounds► Subscribe
7,279,582Retroviral protease inhibiting compounds► Subscribe
6,313,296 Retroviral protease inhibiting compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,284,767

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Colombia5070655► Subscribe
Czech Republic293650► Subscribe
Czech Republic9801762► Subscribe
Czech Republic294246► Subscribe
Czech Republic296915► Subscribe
Czech Republic300127► Subscribe
Czech Republic300131► Subscribe
Germany69619140► Subscribe
Denmark0882024► Subscribe
European Patent Office0876353► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Cantor Fitzgerald
Chubb
McKesson
Colorcon
UBS
Novartis
Moodys
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot